The fifth antibacterial drug designated as a qualified infectious disease product has received US Food and Drug Administration (FDA) approval. Such drugs treat serious or life-threatening infections. The agency expedites its review of these products and doubles their marketing exclusivity period from 5 years to 10 years.
Avycaz combines ceftazidime, a cephalosporin antibacterial drug that was already on the market, and avibactam, a new β-lactamase inhibitor. It will be marketed to treat 2 complicated infections in adults: intra-abdominal infections, administered in combination with metronidazole, and urinary tract infections, including kidney infections.
Rubin R. New Antibacterial Drug Approved. JAMA. 2015;313(13):1306. doi:10.1001/jama.2015.2800
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: